GlycoMimetics Inc. (GLYC) - Utang marang Ekuitas

Due to the humanitarian status of medicine, GlycoMimetics, Inc. (GLYC) developments in the US and Europe are shielded from geopolitics. This chart on GURU.Markets shows a debt-to-equity ratio of 0.00. The business focuses on creating glycobiological agents to combat anemia and oncology. However, a lack of profitability and uncertainty regarding drug trial results create a strong dependence of the firm on external financing.

GLYC - Rasio Total Utang marang Ekuitas GlycoMimetics Corp ing rentang 04.07.2022 - 16.06.2025

Rincian metrik komprehensif lan analitis GlycoMimetics (GLYC)

- rega lan prakiraan konsensus rega:

Bagan rega GlycoMimetics Inc.|GLYC - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar GlycoMimetics|GLYC - Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham GlycoMimetics|GLYC - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku glycomimetics.com|GLYC - Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas GlycoMimetics, Inc.|GLYC - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas GlycoMimetics Inc.|GLYC - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku GlycoMimetics|GLYC - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan GlycoMimetics

Analisis dhasar perusahaan:GlycoMimetics, Inc. (GLYC)

The expansion of the oncology pipeline at GlycoMimetics, Inc. (GLYC) requires significant investments in clinical trials for uprelselela to capture the targeted therapy market. The total liabilities-to-equity ratio quantifies this process, determining the balance between financial leverage and business stability, which allows for an assessment of debt load risk through the debt-to-equity dependency metric.

Analisis perusahaan pesaing